Connecticut Designates Kratom as Schedule I Controlled Substance, Signaling Major Shift for Industry

Connecticut Designates Kratom as Schedule I Controlled Substance, Signaling Major Shift for Industry

Hartford, CT – In a significant move impacting the kratom industry nationwide, Connecticut's Legislative Regulation Review Committee (LRRC) unanimously approved regulations on Tuesday, February 24, 2026, to classify Mitragyna speciosa, commonly known as kratom, and its derivatives, including 7-hydroxymitragynine (7-OH), as Schedule I controlled substances. This decision makes Connecticut the seventh state to implement such a ban, effectively prohibiting the sale, possession, and use of kratom within its borders.

What Happened

The LRRC's vote formalizes a process initiated by House Bill 6855, signed by Governor Ned Lamont in June 2025, which granted the Department of Consumer Protection (DCP) the authority to designate certain substances as controlled. The DCP subsequently submitted its recommendation to schedule kratom, citing concerns over its lack of approved medical use, unregulated sales to all ages, absence of product testing, and potential public health risks, particularly from the more potent derivative, 7-OH. This designation places kratom alongside substances deemed to have a high potential for abuse and no accepted medical use.

Why It Matters to Kratom Merchants and Consumers

For kratom merchants, this news delivers a decisive blow to operations within Connecticut. All businesses previously selling kratom products must immediately cease such activities, as selling, buying, or possessing kratom is now illegal in the state. Non-compliance can lead to severe penalties, including criminal prosecution, fines, and imprisonment. This action further fragments the legal landscape for kratom, creating a complex and inconsistent regulatory environment across the United States.

Consumers in Connecticut are also directly affected, as the purchase, possession, and use of kratom are now outlawed. Individuals found with kratom may face legal consequences. This move eliminates a product many have used for wellness purposes, highlighting the ongoing debate and varying approaches to kratom regulation at the state level.

Compliance Implications

The immediate compliance implication for businesses in Connecticut is straightforward: complete cessation of all kratom-related activities. For merchants operating in other states where kratom remains legal, Connecticut's decision serves as a stark reminder of the volatile regulatory environment. Staying informed about local and state-level legislative changes is paramount, as the legal status of kratom can shift rapidly and without extensive warning. The federal government currently does not classify kratom as a controlled substance, though the U.S. Food and Drug Administration (FDA) has issued warnings and recommended scheduling actions for 7-OH products, contributing to the "high-risk" classification of the industry by payment processors.

What High-Risk Merchants Need to Know About COAs, Lab Testing, and Regulatory Compliance

For high-risk kratom merchants operating in states where the substance is still legal, robust compliance practices are non-negotiable. While Connecticut's ban negates the need for product testing within its borders, for all other legal markets, the following remains critical:

• Certificates of Analysis (COAs): Every batch of kratom product sold should be accompanied by a third-party Certificate of Analysis. These documents are crucial for verifying the alkaloid content, specifically mitragynine and 7-hydroxymitragynine percentages, and ensuring the product's safety. COAs should be recent and tied to specific batch or lot numbers.
• Comprehensive Lab Testing: Beyond alkaloid profiles, products must undergo rigorous testing for contaminants. This includes screening for heavy metals (lead, arsenic, mercury, cadmium, nickel), microbial contaminants (Salmonella, E. coli, yeast, mold), and residual solvents. Such testing is vital for consumer safety, regulatory adherence, and maintaining the industry's credibility.
• Regulatory Compliance: High-risk merchants face heightened scrutiny from payment processors due to inconsistent state laws and elevated chargeback risks. Proactive compliance involves maintaining detailed business entity documentation, ensuring all product descriptions avoid unapproved medical or therapeutic claims, and implementing robust age verification processes. Adherence to standards set by organizations like the American Kratom Association (AKA) through their Good Manufacturing Practices (GMP) program, which includes supplier qualification, documented standard operating procedures, and testing protocols, can further mitigate risks. Selling products in unregulated channels, such as gas stations and smoke shops, is considered high-risk due to a lack of oversight and testing.

Connecticut's decision underscores the ongoing challenges and unpredictability within the kratom industry. For merchants aiming for long-term viability, stringent adherence to quality control, comprehensive lab testing, and proactive regulatory compliance in legal jurisdictions are more critical than ever.